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Evaluating Methods for the Analysis of Rare Variants in Sequence Data
Abstract
A number of rare variant statistical methods have been proposed for analysis of the impending wave of
next-generation sequencing data. To date, there are few direct comparisons of these methods on real
sequence data. Furthermore, there is a strong need for practical advice on the proper analytic strategies
for rare variant analysis. We compare four recently proposed rare variant methods (combined multivariate
and collapsing, weighted sum, proportion regression, and cumulative minor allele test) on simulated
phenotype and next-generation sequencing data as part of Genetic Analysis Workshop 17. Overall, we find
that all analyzed methods have serious practical limitations on identifying causal genes. Specifically, no
method has more than a 5% true discovery rate (percentage of truly causal genes among all those
identified as significantly associated with the phenotype). Further exploration shows that all methods
suffer from inflated false-positive error rates (chance that a noncausal gene will be identified as
associated with the phenotype) because of population stratification and gametic phase disequilibrium
between noncausal SNPs and causal SNPs. Furthermore, observed true-positive rates (chance that a truly
causal gene will be identified as significantly associated with the phenotype) for each of the four methods
was very low (<19%). The combination of larger than anticipated false-positive rates, low true-positive
rates, and only about 1% of all genes being causal yields poor discriminatory ability for all four methods.
Gametic phase disequilibrium and population stratification are important areas for further research in the
analysis of rare variant data.
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Evaluating methods for the analysis of rare
variants in sequence data
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Abstract
A number of rare variant statistical methods have been proposed for analysis of the impending wave of nextgeneration sequencing data. To date, there are few direct comparisons of these methods on real sequence data.
Furthermore, there is a strong need for practical advice on the proper analytic strategies for rare variant analysis.
We compare four recently proposed rare variant methods (combined multivariate and collapsing, weighted sum,
proportion regression, and cumulative minor allele test) on simulated phenotype and next-generation sequencing
data as part of Genetic Analysis Workshop 17. Overall, we find that all analyzed methods have serious practical
limitations on identifying causal genes. Specifically, no method has more than a 5% true discovery rate (percentage
of truly causal genes among all those identified as significantly associated with the phenotype). Further exploration
shows that all methods suffer from inflated false-positive error rates (chance that a noncausal gene will be
identified as associated with the phenotype) because of population stratification and gametic phase disequilibrium
between noncausal SNPs and causal SNPs. Furthermore, observed true-positive rates (chance that a truly causal
gene will be identified as significantly associated with the phenotype) for each of the four methods was very low
(<19%). The combination of larger than anticipated false-positive rates, low true-positive rates, and only about 1%
of all genes being causal yields poor discriminatory ability for all four methods. Gametic phase disequilibrium and
population stratification are important areas for further research in the analysis of rare variant data.
Background
Genome-wide association studies (GWAS) hope to identify variations in the human genome that increase disease
risk. Over the past decade, single-nucleotide polymorphism (SNP) microarrays have been used in GWAS to
explore the association of common variants with disease.
With the advent of next-generation sequencing technology, consideration of rare variants is now possible. A
number of rare variant methods [1-4] have been recently
proposed as first attempts to investigate the contribution
of rare genetic variants to common disease. These methods all take a similar approach in which variants (SNPs)
are aggregated at the gene level. Specifically, all variants
within a gene are assigned to that gene, and the methods
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are designed to test whether, in total, the variants in the
gene show association with the phenotype. To date, there
has been no systematic comparison of the proposed
methods. Furthermore, there has been little to no application of these methods to actual sequence data, and so
little is known about the practical issues that will arise
when applying these methods to real data.
In this paper, we use real genotypes and simulated phenotype data from Genetic Analysis Workshop 17
(GAW17) to provide a systematic and comprehensive
comparison of the power and type I error of each of four
rare variant methods (combined multivariate and collapsing, weighted sum, proportion regression, and cumulative minor allele test) in a variety of scenarios. This
comparison gives practical insights into power and sample size issues in the analysis of next-generation sequencing data in the new wave of GWAS and suggests further
areas of research needed to improve type I error and
power in practice.

© 2011 Luedtke et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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Methods
Data

All analyses presented here are based on data provided by
the organizers of GAW17. Detailed descriptions of the
data and simulation of the disease phenotype are provided
elsewhere [5]. We provide a brief overview here. The data
consist of 697 unrelated individuals genotyped at 24,487
autosomal SNPs contained in at least 1 of 3,205 different
genes. We consider three sets of SNPs. The first set is all
21,355 SNPs with minor allele frequency (MAF) < 0.05;
the second set is a superset of the first, containing all
24,487 autosomal SNPs; and the last set is a subset of the
second set, containing the 13,572 SNPs that are bioinformatically predicted to be nonsynonymous. Because some
genes contain only SNPs with MAF > 5% or only synonymous SNPs, the total number of genes under analysis is
reduced when analyzing these subsamples (the analysis for
SNPs with MAF < 5% uses 2,874 total genes; the analysis
for synonymous SNPs uses 2,196 total genes). All SNP
genotypes are coded as 0 or 1, where 0 means no copies of
the minor allele are present and 1 means that at least one
copy of the minor allele is present. This coding strategy
for SNP genotypes is required by some of the analytic
methods considered and is a reasonable choice for rare
variants. For common variants, of only minor importance
in our analysis, the code represents the presumption of a
dominant disease model.
The organizers of GAW17 simulated a dichotomous disease phenotype (Affected/Not affected) onto the 697 individuals, and that phenotype is the focus of our analyses in
this paper. The dichotomous disease phenotype is caused
by a combination of measured SNPs (162 SNPs in 37
genes) and unmeasured SNPs. Two-hundred separate
simulated phenotype replicates (each based on the same
disease model) were produced. We note that the focus of
our analysis is SNPs with MAF < 5% because the methods
being compared were designed for use on rare variants,
although the other analyses (all SNPs and only nonsynonymous SNPs) are included for comparison.
Rare variant methods

We compare four rare variant statistical methods: combined multivariate and collapsing, weighted sum, proportion regression, and cumulative minor allele test. A
detailed discussion of the first three methods is provided
by Dering et al. [6]. We provide brief overviews of these
three methods here and a more detailed description of the
fourth method.
The combined multivariate and collapsing (CMC)
method [1] combines SNPs within a gene into subgroups
based on some criterion (e.g., MAF threshold) and then
applies a multivariate test (e.g., Hotelling T 2 ) to the
groups to obtain a test statistic. In our implementation of
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the CMC method we group all SNPs in a gene that have
MAF < 0.01 into one subgroup, and all other SNPs
belong to their own groups. We use the Hotelling T2 statistic and its asymptotic distribution to assess statistical
significance.
The next method we consider is the weighted-sum
(WS) method, which calculates a score for each individual by summing the ratio of the genotype to the estimated standard deviation of the variant (under the null
hypothesis) across all variants within the gene [2], effectively putting more weight on variants with lower
MAFs. Scores are then used to rank the individuals, and
a test statistic is obtained by summing the rank of gene
scores for the affected individuals. One thousand phenotype permutations are used to assess the significance of
the WS statistic.
The third method we consider is the proportion
regression (PR) method [3], in which the proportion of
variant sites within a gene containing the rare variant is
regressed against the phenotype. As proposed by Morris
and Zeggini [3], we use the asymptotic test for logistic
regression to evaluate significance.
The last method we consider is the cumulative minor
allele test (CMAT), which uses a 2 × 2 chi-square statistic
to compare the total numbers of rare variants present in
the gene for case subjects and control subjects [4]. Specifically, the CMAT compares two proportions using a chisquare statistic: (1) the proportion of rare alleles in case
subjects, computed as the total number of rare alleles
present within the gene of interest totaled across the case
group divided by the total number of SNP loci within the
gene of interest multiplied by the number of case subjects; and (2) the proportion of rare alleles in the control
subjects, computed as the total number of rare alleles
present within the gene of interest totaled across the control group divided by the total number of SNP loci within
the gene of interest multiplied by the number of control
subjects. Because of the potential for linkage disequilibrium between markers and small counts, the significance of the CMAT statistic is determined by phenotype
permutation (1,000 permutations) instead of the chisquare distribution.
Gene and sample characteristics

In our analysis we use a variety of measures to help
assess power and type I error patterns. We define a
measure of population stratification (P) for each of the
200 replicates by finding the value of the Pearson chisquare test of association between the dichotomous phenotype and the ethnicity of each person in the sample
(CEPH [European-descended residents of Utah], Luhya,
Yoruba, Japanese, Denver Chinese, Han Chinese, and
Tuscan).
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We define a spuriously associated gene as any gene
that is identified as significantly (p < 0.05) associated
with the phenotype in at least 16 of the 200 replicates
for all four methods when analyzing only SNPs with
MAF < 5%, but that is not actually associated with the
disease phenotype. We use a value of 16 because it is
the 96th percentile of a binomial distribution (Bin(n =
200, p = 0.05)) representing the distribution of the number of p-values less than 0.05 under the assumption of
independence of p-values within the gene and across
replicates when the type I error rate is 5%. We note that
the assumption of independence may not be valid
because the genotypes are constant across all 200 replicates. However, the binomial distribution model serves
as a reasonable starting point for considering inflated
type I errors. In addition, our goal in identifying spuriously associated genes is to explore characteristics of
these genes, and so we choose to use a sensitive criterion (0.05) instead of one that adjusts for multiple
testing.
Gametic phase disequilibrium occurs when correlation
between loci occurs beyond what would be expected by
random chance [7]. We define a measure of gametic phase
disequilibrium (G) as the aggregate amount of correlation
between a noncausal SNP and the 162 causal SNPs. Specifically, G is the r2 from a regression model obtained by
regressing the genotype of the noncausal SNP on the genotypes of the 162 causal SNPs.
We also define an overall measure of gametic phase disequilibrium for the entire sample. To do this, we use the
matrix of genotypes of the 24,487 SNPs in the mini-exome
scan for 697 people (each row is a person; each column
represents a different SNP). We first choose 100,000 random pairs of columns, where each pair represents SNPs
on different chromosomes (to ensure no true linkage disequilibrium between SNPs). We then compute an overall
measure of SNP correlation S as the average of the
squared correlations between the genotypes of all 24,487
SNPs across the 697 people:
100,000

S=

∑

ri2

i =1

100, 000

(1)
,

where ri2 is the squared correlation between the ith
randomly selected pair of SNPs.

Results
In the data under analysis, 36 of 3,205 (1.12%) genes are
associated with a simulated phenotype. Table 1 summarizes the results of the four analytic methods run on
all genes across all 200 phenotype replicates. As noted
earlier, the total number of genes under analysis varies

depending on the sample being analyzed: 2,874 for only
rare SNPs (MAF < 5%), 3,205 genes for all SNPs, and
2,196 for all nonsynonymous SNPs. At nominal significance levels of 5% and 0.5% in the analysis that was limited to rare variant SNPs, the PR method identified the
highest percentage of true discoveries (2.41% and 4.20%
of the genes identified as significant) followed by the
CMAT, WS, and CMC methods. However, these values
are only marginally higher than would be obtained by
randomly choosing genes (1.12%).
Table 1 also illustrates how these values are affected
when using all SNPs (including those with MAF > 5%)
and when considering only nonsynonymous SNPs. In
both cases, these changes have only modest effect on
the true-positive rate such that no method yielded a
true-positive rate greater than 5% in any scenario.
False-positive rate

As a first step in exploring why the true discovery rate is so
low for all four methods, we compared the false-positive
rate (nominal a = 0.05) across the genes that do not contain a causal SNP. The false-positive rate is computed as
the proportion of times a gene-replicate combination is
found to have a p-value less than 0.05 out of all total genereplicate combinations for each of the noncausal genes.
Overall false-positive rates for each of the four methods are
found in Table 2.
Although we would expect the false-positive rate to be
at or near the nominal significance level of 5%, we see
increased rates across all methods. These increased rates
can be pinpointed to a subset of the genes that showed
consistent association with the phenotype across replicates and across the four analytic methods. When analyzing rare variants only, we identified 561 spuriously
associated genes out of 2,838 truly noncausal genes (see
Methods section for details), leaving 2,277 noncausal
genes that are not classified as spuriously associated with
the phenotype.
We then performed further analyses to better understand the characteristics of the spuriously associated
genes. We found that, in general, spuriously associated
genes contained significantly more SNPs in the gene
(average of 13.9 vs. 6.9, p < 2.2 × 10−16) and significantly
higher average values of G among the SNPs in the gene
(average of 3.47 vs. 1.87, p = 6.4 × 10 −14 ). We fitted a
multiple logistic regression model to predict whether or
not a gene was spuriously associated with the number of
SNPs in the gene, using the number of SNPs in the gene,
the average MAF of the SNPs in the gene, the average
value of G of SNPs in the gene, and all possible interactions between these variables. We found a significant
interaction between the number of SNPs in the gene and
G. The multiple regression model implicated a combination of a large number of SNPs and larger values of G

Nominal a = 0.05

Method
Total number of significant
associations

Nominal a = 0.005

Number of significant associations that
are actually causal

True
discoveries
(%)

Total number of significant Number of significant associations that
associations
are actually causal

True
discoveries
(%)

Only SNPs with MAF < 5%
WS

281.0

5.69

2.03

52.5

1.56

2.97

CMAT

201.4

4.42

2.19

38.4

1.31

3.44

CMC

256.5

3.80

1.48

38.2

0.92

2.41

PR

184.6

4.46

2.41

27.9

1.17

4.20

All SNPs
WS

348.7

6.81

1.95

76.1

2.05

2.69

CMAT

294.9

4.63

1.57

63.8

1.46

2.28

CMC

361.1

5.16

1.43

64.6

1.23

1.90

PR

285.6

4.74

1.66

53.7

1.39

2.59
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Table 1 Overall ability of the four rare variant methods to identify genes as significantly associated with the phenotype

Nonsynonymous SNPs only
WS

206.1

5.25

2.54

42.3

1.78

4.20

CMAT

173.3

4.19

2.42

35.7

1.44

4.03

CMC
PR

223.3
168.7

4.99
3.88

2.23
2.30

38.5
29.4

1.33
1.38

3.46
4.69

All values are averaged over 200 replicates. WS, weighted sum; CMAT, cumulative minor allele test; CMC, combined multivariate and collapsing; PR, proportion regression.
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Table 2 Overall false- and true-positive rates for the four rare variant methods (significance level 5%)
Rare variant method

False-positive rate (%)

True-positive rate (%)

Only SNPs with MAF < 5%

All SNPs

Only nonsynonymous SNPs

Only SNPs with MAF < 5%

All SNPs

WS

9.7

10.8

9.3

15.8

18.9

Only nonsynonymous SNPs
14.6

CMAT

6.9

9.2

7.8

12.3

12.8

11.6

CMC
PR

8.9
6.3

11.2
8.9

10.1
7.6

10.6
12.4

14.3
13.2

13.9
10.8

All values are averaged over 200 replicates. WS, weighted sum; CMAT, cumulative minor allele test; CMC, combined multivariate and collapsing; PR, proportion regression.
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(larger gametic phase disequilibrium with causal SNPs) as
having synergistic effects in increasing the likelihood of a
gene being identified as spuriously associated with the
phenotype.
In addition to gene characteristics as the cause of the
increased type I error rate, another possible reason for
the inflated type I errors is population stratification.
Using the measure of population stratification P computed for each of the 200 replicates, we computed the
Pearson correlation between population stratification
and the number of genes found as significant by each
method in each of the 200 replicates. All four methods
showed significant positive correlation (p < 6.5 × 10−4 in
all cases) between the measure of population stratification and the number of significantly associated genes in
the replicate (Pearson correlations: 0.24 for the CMC
method, 0.28 for the PR method, 0.26 for CMAT, and
0.26 for the WS method).
To assess the overall effect of both gene characteristics
and sample characteristics on type I error rate, we used
multiple logistic regression. A data set was created for
each of the four methods, with one row for each genereplicate combination. We created a logistic regression
model to predict whether or not the gene-replicate combination was significantly (p < 0.05) associated with the phenotype using gene variables (number of SNPs and G) as
well as P (sample variable). All four logistic regression
models (one for each of the four rare variant methods),
showed significant association for all three variables, suggesting that all factors are contributing to the inflated type
I error rate present in the analysis.
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for the WS method may be the number of noncausal
SNPs in the gene (the more noncausal SNPs, the more
likely the WS method was to find the gene statistically
significant) (details not shown).
Other analyses

We separately analyzed only nonsynonymous SNPs and
the full set of all SNPs (regardless of function and
MAF). Our analyses showed that restricting the set of
SNPs to only nonsynonymous SNPs resulted in a minor
improvement in the true-positive rate compared to analyzing the entire set of rare variants but that analyzing
all SNPs resulted in a decreased true-positive rate (see
Table 1). In addition, larger false-positive rates and
lower true-positive rates were observed when all SNPs
were analyzed simultaneously, whereas false-positive
rates were only modestly increased when using only
nonsynonymous SNPs, with a comparable true-positive
rate (see Table 1).
We also found evidence of gametic phase disequilibrium between SNPs beyond what we would expect to
happen purely randomly. We computed S for the genotype matrix and observed a value of 0.00241. We then
independently permuted the rows within each column of
the SNP genotype matrix and recomputed the value of S
1,000 times. The maximum value obtained through permutation was 0.0017. Because S has an approximately
normal distribution under permutation, we estimated the
mean and standard deviation and calculated a Z score for
the observed data as 8.6, a large value significantly
beyond what would be expected to happen by random
chance.

True-positive rate

The next step in comparing the four different rare variant methods was to compute the power of each method
across the 36 genes containing causal SNPs at a nominal
type I error rate of 0.05. The overall power was computed as the number of times a gene-replicate combination was found to have a p-value less than 0.05 out of
36 × 200 total gene-replicate combinations. Overall
power values for each of the four methods are given in
Table 2.
As expected, all methods showed a strong correlation
between the number of times each gene was found to
be significant (p < 0.05, out of 200 times) and a measure
of each gene’s association with the phenotype (MAF
times b [risk] summed across all SNPs in the gene).
Pearson correlations were 0.63 (CMAT), 0.63 (CMC
method), 0.64 (PR method) and 0.54 (WS method)
across the 36 causal genes.
The WS method showed significantly higher overall
power (18.9%) compared to the other three methods,
which were all comparable. Regression models suggest
that the main reason for the apparent power increase

Considering population stratification

To more formally assess the effect of population stratification on the analysis, we used the covariate adjustment
procedure outlined for CMAT [4], stratifying the sample
on each of the seven subpopulations present in the sample. We reran the stratified CMAT procedure on all 200
replicates for each of the 2,874 genes containing a SNP
with MAF < 5%. The analysis showed some improvement
over the non-population-stratified analysis, although the
results were still far from optimal. Specifically, the stratified CMAT yielded an average of 164.4 significant associations in each replicate for a nominal a of 0.05, lower
than the other four methods (compare to Table 1); however, the percentage of true discoveries was second worst
(1.89%; 3.11 true discoveries per replicate on average).
Similar results were found when a was set to 0.005. The
false-positive rate was the lowest of all methods (5.7%;
compare to Table 2); however, the true-positive rate was
also the lowest (8.6%). Most important, in a multiple
logistic regression analysis assessing the overall effect of
gene and sample characteristics on the type I error rate
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(corresponding analysis in the last paragraph of the
“False-Positive Rate” subsection), all three gene characteristic variables were significant (p < 0.05).

Discussion
Application of recently proposed methods for analyzing
rare variant data has identified a number of important
considerations for their use in practice. Specifically, all
methods suffered from increased false-positive and
decreased true-positive rates.
Paramount among the problems of the rare variant
methods was an inflated false-positive rate. Our analyses
suggest a number of gene-specific characteristics and sample characteristics that contribute to the increased falsepositive rate. First, all methods showed increased falsepositive rates for genes containing more SNPs. These
results were further confirmed by analysis showing better
false-positive control when fewer SNPs were used in the
analysis (e.g., SNPs with MAF < 5% or only nonsynonymous SNPs). That all methods suffered from increased
false positives demonstrates the need for improved rare
variant methods that are less prone to type I errors in
these cases.
Second, gametic phase disequilibrium was strongly associated with type I error. A typical assumption in simulations presented for method development is that little to no
linkage disequilibrium is present in the analysis of rare variant data because of the low allele frequencies. This may be
the case at the population level; that is, the data are unlikely to exhibit linkage disequilibrium between rare variants
with the same gene in any population of interest. However,
in any practical analysis of sequence data, for which the
number of individuals genotyped is significantly less than
the number of variant sites genotyped, it is entirely plausible that two rare variants even on different chromosomes
may realize their minor allele within the same individual.
Or at least, two rare variants may seem to be correlated
merely because each of them occurs only in a few individuals, and some of those individuals are, by chance, the
same for both variants. As shown (in the “Other Analyses”
subsection of the Results section), some gametic phase disequilibrium is expected because of the finite sample size,
but the gametic phase disequilibrium observed in the sample is higher than would have occurred by random chance
alone, suggesting systematic genotyping errors.
Third, population stratification was identified as a
potential cause of the increased false positives (see the
“False-Positive Rate” subsection of the Results section).
This result was confirmed when an additional analysis
using the stratified CMAT showed improved type I
error rates. The investigators proposing the other three
methods (PR, CMC, and WS) give limited attention to
population stratification. Further work is necessary to
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explore approaches for handling population stratification
in rare variant tests.
All methods also suffered from low true-positive rates.
The 36 causal genes analyzed here represent a range of
number of causal SNPs, MAFs, and risks. Expectedly, the
more causal SNPs in the gene, the larger their MAFs; and
the larger the risk, the more power. However, if the 36
genes in this study are well representative of the true distribution of causal SNPs, MAFs, and risks in practice,
then there is some need for concern over the low power
to detect these associations.

Conclusions
Recently proposed rare variant methods showed limited
ability to identify causal genes in the analysis of miniexome scan data because of decreased true-positive and
increased false-positive error rates. Increased error rates
were due to the presence of gametic phase disequilibrium
and population stratification. In general, the methods
also showed oversensitivity to the inclusion of noncausal
variants, suggesting that using only nonsynonymous
SNPs and SNPs with MAF < 5% can yield modestly
improved results.
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